侵袭性早产儿视网膜病变特征及再治疗危险因素
本研究基于2007至2021年23个中心(16个美国、7个非美国)的早产儿视网膜病变数据,分析侵袭性ROP(A-ROP)接受抗VEGF再注射的危险因素。结果显示A-ROP与更低出生体重、更小胎龄及更后部ROP分区相关;出生体重每增加100克再注射风险降低26%,初始使用雷珠单抗较贝伐珠单抗再注射风险更高(风险比4.82)。
要点
- A-ROP患儿平均出生体重712克、胎龄24.8周,均低于非A-ROP患儿。
- 出生体重每增加100克,A-ROP再注射风险降低26%(p=0.041)。
- 初始使用雷珠单抗者再注射风险是贝伐珠单抗的4.82倍(p=0.009)。
核心结论
- A-ROP与更低出生体重、更小胎龄及更后部ROP分区相关,低出生体重和初始雷珠单抗治疗与更高的再注射风险相关。
研究设计与样本
- 回顾性多中心队列研究,纳入2007至2021年23个中心(16个美国、7个非美国)的早产儿ROP数据,使用广义估计方程分析再注射风险。
主要发现
- 1677只受检眼中1600只患ROP,其中283只为A-ROP(平均出生体重712克,平均胎龄24.8周),1317只为非A-ROP(平均出生体重812克,平均胎龄25.9周)。
- A-ROP患儿平均出生体重和胎龄均低于非A-ROP(p<0.001)。
- 在A-ROP病例中,出生体重每增加100克,再注射风险降低26%(p=0.041)。
- 与贝伐珠单抗相比,雷珠单抗与A-ROP眼再注射风险升高相关(风险比=4.82,p=0.009)。
- ROP II区较I区再注射风险高2.48倍(p=0.014),但校正双眼发病后该关联减弱。
关键数值与推荐
- A-ROP再注射风险因素:出生体重每增加100克风险降低26%(p=0.041);雷珠单抗 vs 贝伐珠单抗风险比=4.82(p=0.009);II区 vs I区风险比=2.48(p=0.014,校正双眼发病后减弱)。
临床怎么用
- 对A-ROP患儿应关注低出生体重和初始抗VEGF药物选择,低出生体重及初始使用雷珠单抗者可能需更密切随访再注射风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Aggressive retinopathy of prematurity (A-ROP) is a severe subtype of ROP that can require repeated treatment yet risk factors for retreatment remain incompletely defined. This study aims to identify risk factors for anti-vascular endothelial growth factor (VEGF) re-injection in A-ROP across US-born and non-US-born infants. METHODS: Data from premature infants with ROP were collected across 23 sites (16 USA, 7 non-USA) from 2007 to 2021. A-ROP re-injection risk was evaluated using generalised estimating equations, adjusted for birth weight (BW), gestational age (GA) at birth, ROP zone at injection, hospital site and initial anti-VEGF agent. RESULTS: Of 1677 examined eyes, 1600 had ROP; 283 had A-ROP (mean BW 712 g, mean GA 24.8 weeks) and 1317 had non-A-ROP (mean BW 812 g, mean GA 25.9 weeks). Infants with A-ROP had lower mean BW and GA (p<0.001). Across A-ROP cases, each 100 g increase in BW decreased re-injection risk by 26% (p=0.041). Compared with bevacizumab, ranibizumab was associated with a higher risk of re-injection in A-ROP eyes (risk ratio=4.82, p=0.009). ROP zone II was associated with a 2.48-fold higher risk of re-injection than zone I (p=0.014), which was attenuated after correction for bilaterality. CONCLUSIONS AND RELEVANCE: A-ROP is associated with lower BW, lower GA at birth and more posterior ROP zone than non-A-ROP. Lower BW and initial ranibizumab treatment are related to greater risk of repeat anti-VEGF injection. There was more retreatment in zone II A-ROP eyes compared with those in zone I, which did not persist after correction for bilaterality.
引用
- Liu JZ, Chaaya C, Ahmad N, et al. Aggressive retinopathy of prematurity: characteristics and risk factors for retreatment. Br J Ophthalmol. 2026. PMID: 42665365. doi:10.1136/bjo-2026-330184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。